Brightly colored candies, cereals, chips, and sodas might soon look a lot less vibrant, if U.S. Health and Human Services Secretary Robert F ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

The Food and Drug Administration is again trying to rehire some staffers who were recently fired amid mass layoffs at the ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

The department did not confirm which vaccines the testing would be applied to or how the change would be implemented.

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional ...

A Blue Cross Blue Shield policy will force some patients to self-inject medicine, with potentially dangerous results.

Health insurer Blue Cross Blue Shield just adopted a policy that will force many people with serious asthma and allergy ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...